Towards Health: Recent Episodes
Slice of Healthcare LLC
In this episode Brad Hightower, CEO at Hightower Clinical, and Darshan Kulkari, Regulatory and Compliance Attorney for the Life Sciences at The Kulkarni Law Firm join to discuss the 2022 Pharma Year in Review.
Listen to discover:
- The biggest A-Ha moments and challenges for Pharma this year
- How they see the economic downturn having an impact on the industry
- Where data or technology innovation had the greatest impact on clinical trials and/or drug developments
- Whether FDA guidelines will be a motivator or a hindrance on things like trial diversity next year
- How they see social media channels and digital opinion leaders or influencers' impact on scientific communication and exchange evolving next year
- What they are most excited about for 2023 when it comes to innovation, trials or new developments in drug therapies
To learn more about Hightower Clinical please use the links below:
- Website - LinkedIn
To learn more about The Kulkarni Law Firm please use the links below:
- Website - LinkedIn
Be sure to also check out our guests' own podcasts:
Note to File, hosted by Brad Hightower
Darshan Talks, hosted by Darshan Kulkarni
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
In this episode Meredith Dees, VP of Product at Lokavant & Todd Johnson, VP of Customer Success at Lokavant join to talk about big data, health equity, & the future of clinical trials.
Listen to discover:
- The effect that time & costs have on clinical trials, and how data & analytics can impact these factors for the better
- Why it is critical to have a connected & consistent source of data for optimized trials to avoid disparities when gathering large amounts of data
- Lokavant's recent partnership with H1 and why that felt like an important partnership
- The role of innovation like AI in accelerating the quality and timeliness of trials
- How data/analytics can amplify the efforts of decentralized trials, which are being called the future of bringing medicines to market faster and in a more equitable way.
To learn more about Lokavant please use the links below:
- Website - LinkedIn
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
In this episode Jocelyn Levin, Senior Customer Success Manager at H1 joins to discuss her thoughts on customer support & success for Pharma and Life Science companies
Listen to discover:
- Levin's background & journey at H1
- How Levin defines customer success & how this translates through different environments such as B2B, health tech, and health start-ups
- One of the biggest challenges her clients face when utilizing life science data platforms
- What Levin considers the differences between customer success, experience, and support
- Why customer success is important and why it's important to share the successes with a broader market
- Why is a defined strategy & collaboration important to building a CS team
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
In this episode Stacey Rivkin, Vice President of Client Solutions & Strategy at H1 joins to discuss Uncut GEMS: how treatment leaders with revolutionize Pharma and where to find them.
Listen to discover:
- Rivkin's background in the industry
- Some of the changes she's seen in the pharma, biotech and life sciences industry in the last couple years
- An overview of the different types of key opinion leaders (KOLs) that Medical Affairs teams and Medical Science Liaisons seek out and interact with
- The term Uncut GEMs - what this means, who these people are, and why this segment of KOLs is considered untapped
- How the term KOL can encompass a lot of different providers, and how this is important to diversify the pool of thought leaders that Pharma engages with
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
In this episode Ariel Katz, Co-Founder & CEO at H1 joins to discuss how AI can transform the way Pharma engages thought leaders.
Listen to discover:
- A quick catch-up with Katz
- Why healthcare, and more specifically Life Sciences/Pharma, tend to lag in adopting newer technologies like AI?
- If the data we're receiving now is better, or if we just have a different way to apply it via the new tech
- H1's recent announcements about how how they are changing the game with new AI powered capabilities within the HCP Universe product
- The change management approach LS companies should employ to help Med Affairs and MSL move forward in this new era of AI and big data
- If Katz thinks it will make measuring activities, ROI, metrics, and impact for Medical Affairs more efficient and effective
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
In this episode Alexandra Moens, Director of Product Marketing and Adam Wyckoff, Director of Product, Clinical Trials, at H1 join to discuss Divergent Diversity: Where the world is headed with health equity and diversity in clinical trials and bringing drugs to market.
Listen to discover:
- How Moens and Wyckoff have seen the terms diversity and health equity change and evolve in their own experiences
- How health equity is translated to clinical trials
- What the biggest barrier to reaching diverse patient populations is
- How physicians and investigators, as well as social determinants, within communities and drug companies factor into this
- How data can mitigate or begin to combat this challenge when it comes to clinical trials or with bringing drugs to market
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
Out guest: Robert Consalvo, Senior Director of Sales Engineering & Enablement at H1
In this episode we discuss:
- Consalvo's background & role at H1
- In terms of medical affairs, pharma and life sciences - what Consalvo means by N.B.A, and what actions he's driving for his intended results?
- When talking about pharma - why the role of medical affairs is critical to the success of drug launch and development?
- What roadblocks Consalvo sees some organizations run up against when looking for their next best action?
- When encountering these roadblocks, what’s the best way to pivot and score?
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
Our guest: Anatoly Geyfman, VP of Medical Devices at H1
In this episode we discuss:
- Geyfman's background
- How Geyfman joined H1 by acquisition of his company Carevoyance, how he saw needs in the market that were not being met, and how H1 fit that vision
- How Geyfman views himself as a techno-optimist
- Why it’s even more critical for medical devices to reach underserved populations to achieve better health equity
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
Our guest: Ariel Katz, CEO & Co-Founder at H1
In this episode we discuss:
- Katz's background
- Why he started H1
- H1's values and what they stand for in its brand and vision
- What the future of H1 innovation looks like
Sponsored by: H1 (https://www.h1.co/)
To learn more about H1 please use the links below:
- Website - LinkedIn
Also, be sure to follow Slice of Healthcare on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter